Browse the corpus

Fluticasone is a potent corticosteroid that is available as a pivotal therapeutic option in the management of various respiratory and dermatological conditions. Fluticasone's efficacy extends across asthma, allergic rhinitis, emphysema, and atopic dermatitis, marking it as a versatile agent within the pharmacological arsenal. This activity elucidates the indications, mechanism of action, adverse events, and contraindications of fluticasone, catering to the diverse needs of healthcare professionals navigating the complexities of patient care. The evolution of fluticasone's therapeutic landscape underscores its significance in contemporary medical practice. Recent advancements, including the Food and Drug Administration's approvals for over-the-counter use in hay fever and the novel drug-device combination for chronic rhinosinusitis, exemplify its continued relevance in addressing unmet clinical needs. By embracing evidence-based education and staying abreast of emerging developments, healthcare professionals can administer fluticasone therapy effectively. This activity endeavors to enhance patient outcomes by fostering a culture of continuous learning and informed decision-making, thereby reaffirming fluticasone's pivotal role in optimizing therapeutic interventions across diverse clinical scenarios. Objectives: Identify the mechanism of action of fluticasone. Assess the potential adverse effects of fluticasone. Determine appropriate monitoring for patients using fluticasone. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from fluticasone. Access free multiple choice questions on this topic.

There is documentation of substantial lactic acidosis after an overdose of inhaled salmeterol and fluticasone.[28] The patient inhaled 60 puffs of the combination medication in a suicide attempt and presented with sympathomimetic syndrome, metabolic acidosis, and hyperlactatemia. She received supportive therapy and was within normal health limits the following day.[28] This clinical presentation was likely due to the salmeterol being more than the fluticasone, which lent support to the idea that fluticasone is a relatively safe medication.

Research has revealed that inhaled corticosteroids cross the placenta. However, research has found no significant association between ICS and congenital organ malformations.[29] There have been documented risks to the fetus with maternal asthma exacerbations. The risk-benefit ratio should be a consideration when prescribing ICS to pregnant women.[29] A 6-month observational study found that older patients had a sustained improved knowledge and use of inhalers when educated by an on-staff pharmacist.[30] Optimizing user techniques eventually provides them with the most medication possible per administration. They are more likely to receive benefits and symptom resolution and less likely to change medications when receiving their prescribed dose. Working with pharmacists to provide new and old inhaler users with administration techniques will increase their medication satisfaction and health outcomes.[30] Another study assessed the effect of pretreatment with fluticasone for 6 weeks before seasonal allergen provocation; this was a double-blind, placebo-controlled study. They found significant histologic changes after 4 weeks of treatment with 200 mg of fluticasone twice daily.[31] There were fewer epithelial Langerhans cells, mast cells, T-cells, macrophages, and eosinophils in the nasal mucosa of those who received fluticasone than the placebo group. Cellular influx after allergen exposure was also significantly decreased in this group after 4 weeks of treatment. Fluticasone demonstrated effectiveness in early and late-phase allergic rhinitis.[31] Healthcare practitioners should advise prompt prophylactic fluticasone treatment for patients with allergic nasal symptoms. Since fluticasone is now available in the USA as an over-the-counter medication, health practitioners should work in an interprofessional team to ensure compliance and proper use; this collaborative team approach includes physicians, nurses, and pharmacists, communicating across disciplines to ensure optimal therapeutic outcomes while minimizing adverse effects and patient risk.